Jacobio Pharmaceuticals Group Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Jacobio Pharmaceuticals Group has been growing earnings at an average annual rate of 28.7%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 79.9% per year.
Wichtige Informationen
28.7%
Wachstumsrate der Gewinne
53.7%
EPS-Wachstumsrate
Biotechs Wachstum der Industrie | 11.0% |
Wachstumsrate der Einnahmen | -79.9% |
Eigenkapitalrendite | -39.9% |
Netto-Marge | -1,560.9% |
Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation
May 31Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?
May 29We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely
May 10Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook
Aug 26We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate
Jul 29We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth
Apr 29What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?
Mar 21Aufschlüsselung der Einnahmen und Ausgaben
Wie Jacobio Pharmaceuticals Group Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Jun 24 | 23 | -362 | 44 | 350 |
31 Mar 24 | 43 | -361 | 45 | 361 |
31 Dec 23 | 64 | -359 | 47 | 372 |
30 Sep 23 | 72 | -385 | 45 | 420 |
30 Jun 23 | 81 | -410 | 43 | 468 |
31 Mar 23 | 89 | -391 | 43 | 457 |
31 Dec 22 | 96 | -372 | 43 | 446 |
30 Sep 22 | 123 | -332 | 46 | 391 |
30 Jun 22 | 150 | -292 | 49 | 336 |
31 Mar 22 | 151 | -297 | 47 | 308 |
31 Dec 21 | 153 | -301 | 45 | 281 |
30 Sep 21 | 348 | -570 | 52 | 259 |
30 Jun 21 | 544 | -839 | 60 | 237 |
31 Mar 21 | 515 | -1,177 | 57 | 211 |
31 Dec 20 | 486 | -1,514 | 54 | 186 |
30 Sep 20 | 243 | -1,298 | 65 | 171 |
30 Jun 20 | 0 | -1,082 | 77 | 156 |
31 Mar 20 | 0 | -753 | 74 | 147 |
31 Dec 19 | 0 | -425 | 71 | 139 |
Qualität der Erträge: 1167 is currently unprofitable.
Wachsende Gewinnspanne: 1167 is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 1167 is unprofitable, but has reduced losses over the past 5 years at a rate of 28.7% per year.
Beschleunigtes Wachstum: Unable to compare 1167's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: 1167 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 1167 has a negative Return on Equity (-39.92%), as it is currently unprofitable.